Have a feature idea you'd love to see implemented? Let us know!

AVTX Avalo Therapeutics Inc

Price (delayed)

$9.98

Market cap

$103.73M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$19.41

Enterprise value

$21.83M

Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of ...

Highlights
The company's gross profit has surged by 188% QoQ
Avalo Therapeutics's gross margin has soared by 183% from the previous quarter
Avalo Therapeutics's quick ratio has increased by 41% from the previous quarter but it has decreased by 30% YoY
AVTX's revenue has shrunk by 64% YoY

Key stats

What are the main financial stats of AVTX
Market
Shares outstanding
10.39M
Market cap
$103.73M
Enterprise value
$21.83M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.49
Price to sales (P/S)
12.59
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
26.63
Earnings
Revenue
$820,000
EBIT
-$10.05M
EBITDA
-$9.91M
Free cash flow
-$36.78M
Per share
EPS
-$19.41
Free cash flow per share
-$35.56
Book value per share
$20.38
Revenue per share
$0.79
TBVPS
$85.05
Balance sheet
Total assets
$98.46M
Total liabilities
$75.72M
Debt
$0
Equity
$21.08M
Working capital
$25.47M
Liquidity
Debt to equity
0
Current ratio
1.42
Quick ratio
1.37
Net debt/EBITDA
8.27
Margins
EBITDA margin
-1,208.2%
Gross margin
182%
Net margin
-970.5%
Operating margin
-7,666%
Efficiency
Return on assets
-9.1%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-26.6%
Return on sales
-1,225.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AVTX stock price

How has the Avalo Therapeutics stock price performed over time
Intraday
-0.2%
1 week
4.5%
1 month
-25.69%
1 year
-31.08%
YTD
9.67%
QTD
5.05%

Financial performance

How have Avalo Therapeutics's revenue and profit performed over time
Revenue
$820,000
Gross profit
$1.49M
Operating income
-$62.86M
Net income
-$7.96M
Gross margin
182%
Net margin
-970.5%
The company's gross profit has surged by 188% QoQ
Avalo Therapeutics's gross margin has soared by 183% from the previous quarter
AVTX's operating income has shrunk by 120% YoY and by 17% QoQ
The net margin has surged by 78% since the previous quarter and by 34% year-on-year

Growth

What is Avalo Therapeutics's growth rate over time

Valuation

What is Avalo Therapeutics stock price valuation
P/E
N/A
P/B
0.49
P/S
12.59
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
26.63
The EPS has soared by 97% YoY and by 59% from the previous quarter
The equity has grown by 43% YoY
AVTX's revenue has shrunk by 64% YoY
The P/S is 36% lower than the 5-year quarterly average of 19.8 but 7% higher than the last 4 quarters average of 11.8

Efficiency

How efficient is Avalo Therapeutics business performance
Avalo Therapeutics's ROA has soared by 92% YoY and by 82% from the previous quarter
The ROS has soared by 72% from the previous quarter and by 7% YoY

Dividends

What is AVTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AVTX.

Financial health

How did Avalo Therapeutics financials performed over time
AVTX's total assets is 30% greater than its total liabilities
AVTX's current ratio is up by 43% since the previous quarter but it is down by 33% year-on-year
Avalo Therapeutics's quick ratio has increased by 41% from the previous quarter but it has decreased by 30% YoY
The debt is 100% smaller than the equity
The equity has grown by 43% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.